

# **Guidance document**

# Time limits for authorisation applications

Identification number: ZL000\_00\_014

Version: 6.1

**Valid from:** 28.02.2024



# List of contents

| 1     | Terms, definitions, abbreviations   | 3                      |
|-------|---|------------------------|
| 1.1   | Terms and definitions   | 3                      |
| 1.2   | Abbreviations   | 4                      |
| 2     | Introduction  | 4                      |
| 3     | Objective   | 4                      |
| 4     | Scope   |                        |
| 5     | <b>Description</b> Fehler! Tex  | tmarke nicht definiert |
| 5.1   | Procedure period  | 5                      |
| 5.1.1 | Procedure sections and milestones   | 5                      |
| 5.1.2 | Time limits for authorisation applications  | 6                      |
| 5.2   | Implementation of the time limits   | 6                      |
| 5.2.1 | Technical validation  | 6                      |
| 5.2.2 | Formal control / Formal objection   | 7                      |
| 5.2.3 | Evaluation phase I  | 7                      |
| 5.2.4 | List of questions   | 7                      |
| 5.2.5 | Replies to the List of Questions  | 7                      |
| 5.2.6 | Evaluation phase II   | 3                      |
| 5.2.7 | Labelling   | 3                      |
| 5.2.8 | Review of applicant's input within the framework of the right to a legal decision | •                      |
| 5.2.9 | Right of appeal   | 9                      |
| 6     | Transitional regulationsFehler! Tex   | tmarke nicht definiert |
| 7     | Annex   | 10                     |
| 7 1   | Overview of time limite   | 10                     |



# 1 Terms, definitions, abbreviations

#### 1.1 Terms and definitions

## Applicant time

The total time available to the applicant during the ongoing process of handling the application (e.g. for responding to the List of Questions). This time will be debited to the applicant.

## Time limit category

Group of application types that are processed according to the same time frame (see Annex 1).

#### Procedure period

The total time that can elapse from the date that the application is received until the completion of the application, i.e. the sum of Swissmedic time and applicant time. The procedure periods are divided into different time limit categories (see Annex 1).

#### Procedure section (PS)

The procedure section is the period of time between two milestones of a process, e.g. the procedure sections "Formal control", "Evaluation I", "Evaluation II", "Labelling".

#### Section period

The total time available to Swissmedic from the starting point of a particular phase until its end.

## Milestone (MS)

The breakpoints between the procedure sections are termed milestones, e.g. Doc OK, LoQ, preliminary decision and official decision.

## Swissmedic time

The total time available to Swissmedic to process the application, from receipt of the application until the official decision. It comprises the sum of the section periods.

#### Target time

The point in time at the end of a procedure section, calculated from a starting point and a section period.

#### Administrative time limits

Periods of time set by Swissmedic that must be observed by the applicant (e.g. the applicant time for answering the List of Questions, the applicant time for additional questions raised by Swissmedic, etc.).

#### Additional time (see also "Applicant time")

The submission of additional documentation (requested by Swissmedic or unsolicited) during the processing of an application, or the submission of an application for a variation during an ongoing new authorisation procedure, can result in additional time being necessary, if the resources and scheduling need to be adjusted by Swissmedic as a result of these additional submissions (for exceptions, see the section "Implementation of the time limits").

Each additional time period is debited to the applicant, i.e. the additional time taken will not be recorded against Swissmedic time. The provisions of the FeeO-Swissmedic referring to any associated fee surcharge must be taken into consideration.



#### 1.2 Abbreviations

AAA Accelerated Application Hearing

Ann. Annex

AP Application phase

App. Applicant

CD Calendar days

CM Complementary medicine

Doc. OK Formal aspects of documentation OK eCTD Electronic submission in CTD format

EMA European Medicines Agency

Eval. I and II Evaluation phase I and II

FC Formal control (incl. technical validation)

FO Formal objection

FTP Fast-track authorisation procedure

HMP Human Medicinal Products

LoQ List of Questions
MP Medicinal product

MPI Medicinal product information

MS Milestone

MUMS Minor Use Minor Species NAS New Active Substance

OMCL Official Medicines Control Laboratory

PD Preliminary decision

PIP Paediatric Investigation Plan

PS Procedure section

SMC Swissmedic

TCM Traditional Chinese medicine
TC-comm. Text correction communication

TPO Ordinance of 21 September 2018 on Therapeutic Products

(Therapeutic Products Ordinance, TPO) (SR 812.212.21)

TPLO Ordinance of the Swiss Agency for Therapeutic Products of 22 June 2006 on the

Simplified Licensing of Therapeutic Products and the Authorisation of Therapeutic

Products by the Notification Procedure (SR 812.212.23)

TPLRO Ordinance of the Swiss Agency for Therapeutic Products of 9 November 2001 on the

Licensing Requirements for Therapeutic Products (SR 812.212.22)

VMP Veterinary medicinal products

# 2 Introduction Objective

This document describes the timetable for authorisation procedures and defines the time limits observed by Swissmedic in connection with submitted authorisation applications. Legal provisions are in existence for certain time limits (e.g. appeal deadlines).

Where comparable expertise and processes exist, the processes and application time limits are based on those of the European Medicines Agency (EMA) for the Centralised Procedure. Since



certain provisions of Swiss law concerning the administrative process differ from European law, the EMA requirements cannot be directly transferred to the procedures at Swissmedic.

This guidance document pursues three primary objectives: (1) Make all parties aware of the time limits to be respected by Swissmedic and by the applicant. (2) Explain the procedure to be followed for applications that are incomplete in terms of formal requirements and content. (3) By specifying procedure periods, help the applicant with its planning and enable key data to be recorded on the duration of procedures overall and on individual procedure sections.


# 3 Scope

This guidance document is valid for the Authorisations sector.

# 4 Procedure period

#### 4.1 Procedure sections and milestones

Applications for new authorisations usually include the following procedure sections (PS) and milestones (MS).



**Key:** Eval. = Evaluation; LoQ = List of Questions; PD = Preliminary Decision

Figure 1: Possible milestones and procedure sections in the authorisation procedure

# MS "Application received"

Swissmedic receives and dates the application.

#### AP "Formal control and technical validation"

On receipt, the formal aspects of the application are checked. If the documentation for the application is complete and formally correct, the application is formally accepted as valid. If there are formal shortcomings in the application, however, a formal objection is sent to the applicant. On receipt, the technical aspects of eCTD applications are validated prior to the formal control (technical validation). Any technical shortcomings must be corrected by the applicant before the formal control can begin. The formal control is carried out in the same way as that for the paper process.

## MS "Doc formally OK"

Swissmedic accepts the application as being in order from a formal perspective. The applicant is informed only if a formal objection was raised beforehand.

#### PS "Evaluation I"

After the "Doc formally OK" MS, the application is evaluated. Based on Evaluation I, a *List of Questions* is drawn up and sent to the applicant.



#### MS "List of Questions"

The questions relating to the content of the application are sent to the applicant.

#### PS "Evaluation II"

The replies to the List of Questions are evaluated within the context of Evaluation II. Evaluation II ends with the preliminary decision, which can be positive or negative.

#### MS "Preliminary Decision"

The preliminary decision is sent to the applicant and constitutes a right to a hearing. The decision does not cover the medicinal product information texts, which are finalised during the phase between the preliminary decision and the official decision.

#### PS "Labelling"

In response to a positive preliminary decision the applicant submits the revised medicinal product information texts and packaging elements. The texts must be revised by the applicant in a way that permits their approval. After a successful revision of the medicinal product information texts (MPI texts), and once any other requirements that have been communicated to the applicant are met, Swissmedic makes its official decision.

If the evaluation of the applicant's response to the preliminary decision reveals that further revisions are necessary in order correct the medicinal product information texts and/or packaging elements, these are sent to the applicant with a text correction communication. The time needed to complete such additional text correction rounds is debited to the applicant. If a second text correction round is necessary, the applicants are also invoiced for the processing costs involved, in addition to the procedure-related flat fee.

#### MS "Official decision"

The official decision marks the completion of the application and will be sent to the applicant.

Not all types of application undergo all the procedure sections and milestones. If, for example, there are no questions arising from Evaluation I, the List of Questions milestone is skipped.

# 4.2 Time limits for authorisation applications

In order to effectively plan resources and prevent the unnecessary lengthy processing of applications,

Swissmedic sets administrative time limits for applicants. These are not legally stipulated time limits. Procedural time limits are established by an interim order, and the applicant is informed of these in writing; the same applies to any threatened consequences resulting from the failure to comply with the time limits. Upon request, procedural time limits may, in principle, be extended once only.

The time limits are measured in calendar days and include weekends and public holidays. The total processing time for an authorisation procedure (procedure period) is calculated as the sum of the total of Swissmedic and applicant times.

A complete list of procedure periods can be found in Ann. 1.

# 5 Implementation of the time limits

#### 5.1 Technical validation

For applications in eCTD format, a technical validation takes place prior to the formal control. Swissmedic informs the applicant of its findings with regard to the technical validation. If the electronic data do not satisfy the requirements, the applicant must make the necessary corrections and resubmit



the data, usually within 30 CD. The time needed for such technical corrections are deducted from the time available to the applicant for correcting formal shortcomings.

Technical objections can be made more than once. Exceptions to this are applications for variations of types IA, IA<sub>IN</sub> and IB for human medicinal products and variations without assessment (or with assessment but with "reduced" time limit) for veterinary medicinal products, for which technical objections may only be made once.

## 5.2 Formal control / Formal objection

In the case of a formal objection, the time needed by the applicant to correct and complete the documentation and the time needed by Swissmedic for the formal control thereof is then debited to the applicant. The time specified in Ann. 1 is again available to Swissmedic. A "Doc OK" notification is usually issued only if a formal objection has previously been raised.

Formal objections are usually issued only once. If the applicant is unable to resolve the formal shortcomings after the objection is issued, Swissmedic will not process the application. For minor variations of types IA, IA<sub>IN</sub> and IB for human medicinal products resp. variations without assessment and variations with assessment but with time limit "reduced" for veterinary medicinal products, a corresponding interim order is issued instead of a formal objection.

# 5.3 Evaluation phase I

- Evaluation phase I begins after the successful completion of the formal control and when the processing of the application begins (milestone "Doc. OK").
- If the scientific documentation proves to be incomplete during Evaluation phase I, and if the applicant is required in the LoQ process to send additional documentation, additional time may be added to the process.
- The unsolicited submission of new evaluation documentation (e.g. applications for variations during ongoing new authorisation procedures) during Evaluation phase I can lead to the time limit being reset to the point "Doc OK". This is implemented as additional time and debited to the applicant. Exceptions to this rule are the subsequent submission of long-term stability data, validation reports on the manufacturing process for the active substance/finished product and documents that, during a pre-submission meeting or on request by the applicant, Swissmedic agreed to accept at a later date.

# 5.4 List of questions

The table in Ann. 1 shows the cases in which a List of Questions is anticipated in the standard process. Swissmedic reserves the right, for every type of application, to issue a list of questions when it is necessary to obtain additional information from the applicant in order to make an informed decision.

If there is no need to send questions to the applicant within the framework of an application, it is possible to omit the list of questions.

# 5.5 Replies to the List of Questions

Swissmedic begins the evaluation of the replies to the list of questions once the specified time limit for the "Answer to the LoQ" procedure expires, as long as the answers to all aspects of the content have been received, and are both complete and correspond to the formal requirements. It may be possible to begin Evaluation II earlier than scheduled, provided the answers are received



- at least 30 days before the specified time limit expires and Swissmedic has the necessary resources to begin the evaluation early.
- If there are shortcomings with regard to the quality of the documents submitted in the reply to the LoQ, Swissmedic may return those texts affected to the applicant to be corrected or completed.
- For new applications and applications for variations, Swissmedic may request the submission of samples of the medicinal product for analysis, which the applicant must send to the Official Medicines Control Laboratory (OMCL). In such cases, the submission of the samples of the medicinal product is a prerequisite for Evaluation phase II to begin.
- If, in order to answer the List of Questions, the applicant submits new evaluation documentation in addition to that required to respond to the questions, Swissmedic decides on a case-by-case basis whether it will carry out a second Evaluation phase I with a related second List of Questions. The time available in this case is debited to the applicant and usually corresponds to the time limits for Evaluation phase I. In individual cases, additional time can also be debited to the applicant in Evaluation phase II; in this case a preliminary decision is issued without a second list of questions.
  - Exceptions to this rule are the subsequent submission of long-term stability data, validation reports on the manufacturing process for the active substance/finished product and documents that Swissmedic has agreed, on request, to accept at a later date.
- Regarding subsequent submission of evaluation documentation owing to the scientific documentation being incomplete, please see section 5.3, point 2.

## 5.6 Evaluation phase II

- The submission of new documents during Evaluation phase II (or of applications for variations during ongoing new authorisation processes) leads to the procedure being reset to the beginning of Evaluation phase II. If the documentation concerned is extensive, a decision is taken on a case-by-case basis whether to reset the procedure to Evaluation Phase I back to "Doc formally OK". In these cases, corresponding additional time is debited to the applicant. Exceptions to this rule are the subsequent submission of long-term stability data, validation reports on the manufacturing process for the active substance/finished product and documents that Swissmedic has agreed, on request, to accept at a later date.
- In order to streamline the process and largely avoid repeated rounds of the process, a list of questions is not usually sent after Evaluation phase II. Instead, the corresponding preliminary decision is issued directly. A second list of questions may, if necessary, be sent in exceptional cases as mentioned under "Replies to the LoQ".
- The scheduled official decision, as determined by Swissmedic, is communicated to the applicant at the milestone "Preliminary decision". The following so-called "Labelling phase" is primarily intended for revising the medicinal product information texts and the packaging elements.

# 5.7 Labelling

- Following the issue of a positive preliminary decision, Swissmedic expects evidence that any additional conditions for granting authorisation have been fulfilled. Swissmedic then begins the evaluation of the replies to the preliminary decision once the specified time limit for the applicant's "Reply to the preliminary decision" expires, provided the documents requested are complete and comply with the formal requirements.
  - If the applicant has requested an extension of the time limit to provide its answers to the preliminary decision, the evaluation may begin, on a case-by-case basis, only after the extended time limit has expired.
- The corrections to the text elements (medicinal product information, labels, cartons, etc.) requested by Swissmedic must be included as revisions in the draft texts and submitted to the Agency for approval. If Swissmedic is able to approve the text elements and if all authorisation conditions are fulfilled, the approved texts are returned to the applicant with the official decision.



- If it is not possible to approve the MPI texts and packaging elements that the applicant has corrected and completed, the texts are returned to the applicant within the pre-defined time limit for correction. The time available to Swissmedic for reviewing and approving MPI texts and packaging elements in accordance with Ann. 1 is only calculated for the evaluation of the MPI texts and packaging elements that are submitted with the reply to the preliminary decision.
- For the processing of subsequent text review rounds, the same times are available to Swissmedic as those for the application phase "Evaluation of the reply to the preliminary decision". The time taken for these additional text review rounds is debited to the applicant.

# 5.8 Review of applicant's input within the framework of the right to a legal hearing and official decision

Prior to taking a decision, Swissmedic reviews the applicant's input within the framework of the right to a legal hearing and examines the intended decision in the light of this input. Swissmedic then takes its official decision.

# 5.9 Right of appeal

An appeal may be lodged against the official decision within 30 days of issue of the decision.



# **Annex - Overview of time limits**

Unless otherwise defined, the time limits shown in the table apply to human and veterinary medicinal products

# Meetings

| Scientific Advice Meeting and Presubmission Meeting |   |
|---|---|
| Review of the application by Swissmedic             | Usually within 2 to 4 weeks of receipt of submission          |
| Scheduling Meeting                                  | Usually within 4 to 8 weeks of receipt of submission          |
| Review of the protocol submitted by the applicant   | Usually within 2 weeks of receipt of the protocol             |
| Clarification Meeting                               |   |
| Submission of the meeting request                   | Within 2 weeks of receipt of the List of Questions            |
| Review of the application by Swissmedic             | Usually within 1 to 2 weeks of receipt of the meeting request |
| Scheduling Meeting                                  | Usually within 3 to 6 weeks of receipt of the meeting request |
| Review of the protocol submitted by the applicant   | Usually within 2 weeks of receipt of the protocol             |

# **Applications**

| Time limit categories / Application types | Swissmedic:<br>Formal<br>control | Applicant: Correction of documents subject to formal objection | Swissmedic:<br>Eval I | Applicant:<br>Reply to<br>LoQ | Swissmedic:<br>Eval II | Applicant:<br>Reply to PD | Swissmedic:<br>Eval. of<br>reply to PD | Total App.<br>time | Total SMC<br>time    |
|---|----------------------------------|--|-----------------------|-------------------------------|------------------------|---------------------------|--|--------------------|----------------------|
| Clarification of FTP application (AAA)    | 5                                | 30   | 30 <sup>1</sup>       | n.a.                          | n.a.                   | n.a                       | n.a                                    | n.a                | 40 - 50 <sup>2</sup> |

<sup>&</sup>lt;sup>1</sup> 6 – 8 weeks after receipt of the FTP application, the AAA takes place. SMC takes the binding decision at the AAA. The official decision is communicated to the applicant after the AAA. Provided the SMC has no objections to the FTP application and no further clarifications are required, the official approval decision for the FTP application is issued directly after the "Review I" phase.

<sup>&</sup>lt;sup>2</sup> Depends on timing of AAA



| Clarification of application for<br>temporary authorisation procedure<br>HMP (AAA) | 5  | 30 | 30 <sup>3</sup> | n.a. | n.a. | n.a. | n.a. | n.a. | 40 – 502 |
|--|----|----|-----------------|------|------|------|------|------|----------|
| Clarification of application for temporary authorisation VMP                       | 5  | 30 | 25              | n.a. | n.a. | 30   | 20   | 60   | 50       |
| Clarification of application for MUMS status                                       | 30 | 60 | 30              | n.a. | n.a. | 90   | 30   | 150  | 90       |
| Clarification of application for<br>Orphan Drug status                             | 30 | 60 | 90              | 90   | 60   | 90   | 30   | 240  | 210      |

ZL000\_00\_014\_WL - Wegleitung | 6.1 | 28.02.2024

<sup>&</sup>lt;sup>3</sup> 6 – 8 weeks after receipt of the temporary authorisation application, the AAA takes place. SMC takes the binding decision at the AAA. The official decision is communicated to the applicant after the AAA. Provided the SMC has no objections to the temporary authorisation application and no further clarifications are required, the official approval decision for the temporary authorisation application is issued directly after the "Review I" phase.



#### **New authorisations and extensions**

| Time limit categories / Application types   | Swissmedic:<br>Formal<br>control | Applicant: Correction of documents subject to formal objection | Swissmedic:<br>Eval I | Applicant:<br>Reply to<br>LoQ | Swissmedic:<br>Eval II | Applicant:<br>Reply to PD | Swissmedic:<br>Eval. of<br>reply to PD | Total App.<br>time | Total SMC<br>time |
|---|----------------------------------|--|-----------------------|-------------------------------|------------------------|---------------------------|--|--------------------|-------------------|
| New authorisations  | 30                               | 60   | 120                   | 90                            | 90                     | 60 <sup>4</sup>           | 90                                     | 210                | 330               |
| NAS, known active substances, MP as per<br>Art. 12 para. 5 TPLO / Biosimilar  |                                  |  |                       |                               |                        |                           |  |                    |                   |
| Parallel import   |                                  |  |                       |                               |                        |                           |  |                    |                   |
| Herbal medicinal products, CM with/without indication, reduced dossier  |                                  |  |                       |                               |                        |                           |  |                    |                   |
| CM: Basic company dossier, master dossier, sample quality doc. Asian MP   |                                  |  |                       |                               |                        |                           |  |                    |                   |
| Procedure with prior notification New authorisations according to Ann. 1 no. 1 FeeO-Swissmedic  | 10                               | 10   | 100                   | 90                            | 90                     | 604                       | 64                                     | 160                | 264               |
| Authorisation extensions (Art. 24 TPO)  | 30                               | 60   | 120                   | 90                            | 90                     | 60 <sup>4</sup>           | 90                                     | 210                | 330               |
| Temporary authorisation   | 5                                | 60   | 65                    | 90 <sup>5</sup>               | 50                     | 60 <sup>4</sup>           | 20                                     | 210                | 140               |
| Fast-track authorisation procedure  | 5                                | 60   | 65                    | 905                           | 50                     | 60 <sup>4</sup>           | 20                                     | 210                | 140               |
| FTP for NAS / known active substances (incl. MP as per Art. 12 para. 5 TPLO) / Biosimilar and authorisation extensions as per Art. 24 TPO |                                  |  |                       |                               |                        |                           |  |                    |                   |
| Co-Marketing  | 30                               | 60   | 30                    | 30                            | 30                     | 30                        | 30                                     | 120                | 120               |
| Evaluation of conditions  | 30                               | 60   | 120                   | 90                            | 90                     | 60 <sup>4</sup>           | 90                                     | 210                | 330               |
| Notification procedure as per Art. 15 TPA   | 30                               | 60   | 60                    | n.a.                          |                        | 60 <sup>4</sup>           | 90                                     | 120                | 180               |
| Notification procedure for veterinary medicinal products  | 30                               | 60   | 60                    | n.a.                          |                        | 604                       | 30                                     | 120                | 120               |

 $<sup>^{\</sup>rm 4}$  In the event of a PD rejection, companies have 30 CD to respond to the PD.

<sup>&</sup>lt;sup>5</sup> A six-day submission window before the <u>published HMEC date</u> must be factored in for the submission of answers to the LoQ for both fast-track authorisations and applications for temporary authorisation.



# **Variations**

| Time limit categories / Application types   | Swissmedic:<br>Formal<br>control | Applicant:<br>Correction<br>of<br>documents<br>subject to<br>formal<br>objection | Swissmedic:<br>Eval I   | Applicant:<br>Reply to<br>LoQ | Swissmedic:<br>Eval II | Applicant:<br>Reply to PD | Swissmedic:<br>Eval. of<br>reply to PD | Total App.<br>time | Total SMC<br>time |
|---|----------------------------------|--|---|-------------------------------|------------------------|---------------------------|--|--------------------|-------------------|
| Type IA / IA <sub>IN</sub><br>(Art. 21 TPO)   | n.a.                             | n.a.   | 30 <sup>6</sup><br>(time to interim order /<br>official decision) | n.a.                          | n.a.                   | n.a.                      | n.a.                                   | n.a.               | 30                |
| Variations without assessment VMP (Art. 25a TPO)  | n.a.                             | n.a.   | 30 <sup>6</sup><br>(time to interim order /<br>official decision) | n.a.                          | n.a.                   | n.a.                      | n.a.                                   | n.a                | 30                |
| Type IB<br>(Art. 22 TPO)  | 10                               | 30   | 60 <sup>7</sup><br>(time to interim order /<br>official decision) | n.a.                          | n.a.                   | n.a.                      | n.a.                                   | 30                 | 70                |
| Variation with assessment VMP "reduced" time limit (Art. 25b TPO)   | 10                               | 30   | 60 <sup>7</sup><br>(time to interim order /<br>official decision) | n.a.                          | n.a.                   | n.a.                      | n.a.                                   | 30                 | 70                |
| Type II<br>(Art. 23 TPO)  | 30                               | 60   | 120   | 60                            | 70                     | 60 <sup>8</sup>           | 50                                     | 180                | 270               |
| Variations with assessment VMP<br>"Standard" time limit<br>(Art. 25b TPO)                                     | 30                               | 60   | 120   | 60                            | 70                     | 608                       | 50                                     | 180                | 270               |
| Type II - Procedure with prior notification Additional indication according to Ann. 1 no. 5.1 FeeO-Swissmedic | 10                               | 10   | 100   | 60                            | 70                     | 608                       | 36                                     | 130                | 216               |
| Type II - Temporary authorisation procedure Additional indication according to Ann. 1 no. 5.1 FeeO-Swissmedic | 5                                | 60   | 65  | 60                            | 50                     | 608                       | 20                                     | 180                | 140               |

<sup>&</sup>lt;sup>6</sup> Unless informed otherwise by SMC, the variation is considered to be accepted 30 CD after receipt of the application. In the case of an interim order, the applicant has 30 CD to correct the shortcomings.

<sup>&</sup>lt;sup>7</sup> Unless informed otherwise by SMC, the variation is considered to be accepted 70 calendar days (10+60 CD) after receipt of the application. In the event of an interim order, the applicant has 30 CD to correct the shortcomings.

<sup>&</sup>lt;sup>8</sup> In the event of a PD rejection, companies have 30 CD to respond to the PD.



| Type II - Fast-track authorisation procedure Additional indication according to Ann. 1 no. 5.1 FeeO-Swissmedic | 5 | 60 | 65 | 60   | 50   | 60 <sup>9</sup> | 20 | 180 | 140 |
|--|---|----|----|------|------|-----------------|----|-----|-----|
| Typ II - Safety-relevant variations<br>(Art. 23 TPO)   | 5 | 10 | 35 | n.a. | n.a. | 30              | 20 | 40  | 60  |
| Safety-relevant variation with assessment VMP (Art. 25b TPO)   | 5 | 10 | 35 | n.a. | n.a. | 30              | 20 | 40  | 60  |

<sup>&</sup>lt;sup>9</sup> In the event of a PD rejection, companies have 30 CD to respond to the PD.



# Other application types

| Time limit categories / Application types   | Swissmedic:<br>Formal<br>check | Applicant: Correction of documents subject to formal objection | Swissmedic:<br>Eval I | Applicant:<br>Reply to<br>LoQ | Swissmedic:<br>Eval II | Applicant:<br>Reply to PD | Swissmedic:<br>Eval. of<br>reply to PD | Total App.<br>time | Total SMC<br>time |
|---|--------------------------------|--|-----------------------|-------------------------------|------------------------|---------------------------|--|--------------------|-------------------|
| Renewal of the authorisation  | 30                             | 10   | 60                    | n.a.                          |                        | 30                        | 60                                     | 40                 | 150               |
| Extension of temporary authorisation  | 10                             | 10   | 20                    | n.a.                          |                        | 10                        | 20                                     | 20                 | 50                |
| Renewed authorisation   | 30                             | 60   | 60                    | n.a.                          |                        | 60 <sup>10</sup>          | 60                                     | 120                | 150               |
| Waiver of authorisation of a preparation  | 10                             | 10   | 20                    | n.a.                          |                        | 10                        | 20                                     | 20                 | 50                |
| Notification according to Art. 8a TPO (No marketing / Interruption of distribution) | n.a.                           | n.a.   | 30                    | n.a.                          | n.a.                   | n.a.                      |  | 0                  | 30                |
| Confirmation of complete fulfilment of the PIP <sup>11</sup>                        | 10                             | 10   | 20                    | n.a.                          |                        | 10                        | 20                                     | 20                 | 50                |

In the event of a PD rejection, companies have 30 CD to respond to the PD.
 In the case of a Swissmedic confirmation, an official decision is made directly after Evaluation phase I.



# **Change history**

| Version | Change   | sig    |
|---------|--|--------|
| 6.1     | New layout, no content adjustments to the previous version.  | tsj    |
| 6.0     | Due to expansion of scope of temporary authorisations: New inclusion of time limits for temporary additional indications in Annex 1  | stb    |
| 5.0     | Correction in Annex 1: Deletion of application type conversion of temporary to regular authorisation   | stb/lm |
| 4.0     | Adaptation of guidance document due to new structure for VMP variations (early revision of VMP regulations)  | fg/ps  |
|         | Details of FTP application procedure / temporary authorisation deadlines   |        |
| 3.2     | Correction of the footnote in annex 1  | stb    |
| 3.1     | Formal adjustments to the header and footer  | dei    |
|         | No content adjustments to the previous version.  |        |
| 3.0     | Annex 1 – Overview of time limits: Explanation that companies have 30 calendar days to respond if the preliminary decision is a rejection.                                       | stb    |
| 2.1     | Annex 1 – Overview of time limits: Explanation regarding the six-day submission window for responses to the LoQ in fast-track and temporary authorisation procedures.            | dts    |
| 2.0     | Correction of Time limit categories / Application types, Variation Type IB, Correction of documents subject to formal objection: 30 CD. Correction of the footnote 3 on page 11. | stb    |
| 1.0     | Implementation of TPO4   | dts    |